Latest Breaking News On - Atypical antipsychotics - Page 5 : comparemela.com

Teva Pharma (TEVA) Presents Real-World Data for AUSTEDO Tablets

Teva Pharma (TEVA) Presents Real-World Data for AUSTEDO Tablets
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United statesEden kleinYael ashmanEric hughesSanjeev sharmaKelley doughertyAndrew cutlerTeva pharmaceuticalsTeva neuroscience incNational alliance on mental illnessTeva pharmaceutical industries ltdSubcutaneous administration olanzapine forDrug administrationTeva pharmaceutical industriesPsych congress elevateNational pregnancy registry for atypical antipsychotics

Teva Presents Real-World Data for AUSTEDO® (deutetrabenazine) Tablets with 4-Week Patient Titration Kit at Psych Congress Elevate 2023

START study provides real-world data for AUSTEDO with the use of a 4-week patient titration kit for adults with tardive dyskinesia , including utilization and patient satisfaction AUSTEDO is the. | June 10, 2023

United statesAndrew cutlerEric hughesDrug administrationTeva pharmaceuticalsTeva neuroscience incPsych congress elevateSubcutaneous administration olanzapine forNeuroscience education instituteMental health services administrationNational alliance on mental illnessTeva pharmaceutical industries ltdNational pregnancy registry for atypical antipsychoticsTeva pharmaceutical industriesExecutive vice presidentChief medical officer

Teva to Present Data Demonstrating UZEDY™ (risperidone) Extended-Release Injectable Suspension Significantly Prolonged Time to Impending Relapse for Adults with Schizophrenia at the American Psychiatric Association s 2023 Annual Meeting

UZEDY significantly reduced the risk of relapse by up to 80% and prolonged the time to impending relapse by up to 5.0 times while having a similar safety profile to other formulations of. | May 20, 2023

United statesJohn kaneRichard jacksonEric hughesNational alliance on mental illnessNational pregnancy registry for atypical antipsychoticsTeva pharmaceuticalsMental health services administrationTeva neuroscience incUs national institutes of healthDepartment of psychiatryTeva pharmaceutical industries ltdAmerican psychiatric associationTeva pharmaceutical industriesRisperidone subcutaneous extended release studyMaintenance treatment

Olanzapine Effective for Higher-Risk Chemo-Induced Nausea

The antipsychotic improves on standard antiemetic therapy in patients known to be more prone to nausea and vomiting with chemotherapy.

United statesMasakazu abeMellar davisHamamatsu university school of medicineGeisinger health systemPalliative care departmentNational comprehensive cancer networkAmerican society of clinical oncologyHamamatsu university schoolAmerican societyClinical oncologyChemotherapy induced nausea and vomitingPatient safetyAdverse effectsSide effectsNeuroleptic drugs

Teva and MedinCell Announce FDA Approval of UZEDY (risperidone) Extended-Release Injectable Suspension, a Long-Acting Subcutaneous Atypical Antipsychotic Injection, for the Treatment of Schizophrenia in Adults

This new treatment provides adults living with schizophrenia a long-acting formulation that offers flexible 1- and 2-month dosing intervals1 In a Phase 3 clinical trial, UZEDY demonstrated

United statesChechnya and ingushetiyaRichard francisNicolas merigeau newcapChristophe douatMedincell euronextDavid heuzEden kleinYael ashmanChristoph correllSanjeev sharmaKelley doughertyNational pregnancy registry for atypical antipsychoticsGlobal healthDrug administrationUs department of justice